论文部分内容阅读
局部应用LAK细胞治疗恶性神经胶质瘤的效果一直令人失望。以抗靶细胞单克隆抗体(McAb)与抗CD3McAb结合组成的双特异性杂交抗体前处理外周血T细胞,能大大增强其体外抗靶癌细胞的杀伤活性。体外研究与动物模型实验均表明以该双特异性抗体行特异性定向治疗,不仅能增强效应T细胞的溶解潜力,而且也能诱发效应细胞与靶细胞的交叉连接;经双特异性抗体处理的LAK细胞识别和溶解靶细胞的效能优于未经处理者。作者报告应用双特异性抗体处理的LAK细胞对恶性神经胶质瘤行特异性定向治疗的初步临床结果。
The use of LAK cells for the treatment of malignant gliomas has been disappointing. Pretreatment of peripheral blood T cells with a bispecific hybrid antibody consisting of a combination of anti-target cell monoclonal antibody (McAb) and anti-CD3 McAb can significantly enhance its anti-target cancer cell killing activity in vitro. Both in vitro studies and animal model experiments showed that specific targeted treatment with this bispecific antibody not only enhances the lytic potential of effector T cells, but also induces cross-linking between effector cells and target cells; treatment with bispecific antibodies The efficacy of LAK cells to recognize and lyse target cells is better than that of untreated ones. The authors report preliminary clinical results of specific targeted treatment of malignant gliomas by using bispecific antibody-treated LAK cells.